Librela works by blocking a specific pain-signaling protein called nerve growth factor (NGF) before it can activate pain receptors in your dog’s body. It’s a monthly injection approved for controlling osteoarthritis pain in dogs, and it represents a fundamentally different approach from traditional painkillers like anti-inflammatory drugs. Instead of reducing inflammation after it starts, Librela intercepts one of the key chemical messengers that makes arthritic joints hurt in the first place.
The Role of Nerve Growth Factor in Joint Pain
Nerve growth factor is a protein released by immune cells and cartilage cells in and around joints. In a healthy joint, NGF is present at low levels. But in dogs with osteoarthritis, the concentration of NGF in joint fluid rises significantly. Research measuring NGF in synovial fluid found that dogs with chronic lameness had levels roughly double those of healthy dogs, a difference that was statistically significant.
When NGF levels climb, the protein binds to specialized receptors on pain-sensing nerve endings in and around the joint. The primary receptor it targets is called TrkA, which sits on peripheral nerve fibers. Once NGF locks onto TrkA, it triggers a cascade that makes those nerve endings more sensitive to pain. Over time, this process doesn’t just amplify pain signals at the joint itself. It can also rewire how the spinal cord and brain process those signals, a phenomenon called central sensitization. That’s why dogs with chronic osteoarthritis often seem to hurt more and more over time, even when the physical damage to the joint hasn’t dramatically changed.
How Librela Blocks the Pain Signal
Librela’s active ingredient, bedinvetmab, is a monoclonal antibody designed to be a near-perfect match for canine biology. It binds directly to NGF molecules circulating in your dog’s body, essentially wrapping around them so they can no longer attach to either of their two receptors on nerve endings (TrkA and p75). With NGF physically blocked from reaching those receptors, the pain amplification process is interrupted at its source.
Think of it like a key and lock system. NGF is the key, and pain receptors are the lock. Librela works by grabbing the key before it reaches the lock, so the door to heightened pain signaling never opens. Because bedinvetmab is built from canine antibody components rather than being a foreign chemical, your dog’s immune system is less likely to treat it as an invader. This is what makes it a “fully caninized” antibody.
How It Differs From Anti-Inflammatory Painkillers
For decades, NSAIDs have been the standard treatment for osteoarthritis pain in dogs. These drugs work by blocking enzymes involved in producing inflammatory chemicals called prostaglandins. They reduce swelling and pain, but they also affect the stomach lining, kidneys, and liver, because prostaglandins play protective roles in those organs too.
Librela takes an entirely different route. It doesn’t touch the inflammatory pathway at all. Instead, it targets the nerve sensitization pathway through NGF. This distinction has practical consequences for side effects. In a head-to-head clinical trial comparing Librela to meloxicam (a common veterinary NSAID), the meloxicam group reported 17 adverse events, nine of them gastrointestinal, while the Librela group reported four. The number needed to harm, a measure of how many patients you’d treat before one experiences a side effect compared to the alternative, was just 5 for meloxicam relative to Librela.
That said, Librela is not an anti-inflammatory. If your dog’s pain has a large inflammatory component, the two approaches may work differently depending on the situation. The safety of using Librela and NSAIDs together has not been established, so they’re generally not combined.
What the Injection Looks Like in Practice
Librela is given as a subcutaneous injection, meaning it goes just under the skin, once a month at your vet’s office. The minimum dose is 0.5 mg per kilogram of body weight. Your vet selects the appropriate vial size based on your dog’s weight, and the injection itself takes only a moment.
Because it’s a monoclonal antibody rather than a traditional drug, Librela isn’t processed through the liver or kidneys the way most medications are. Antibodies are broken down naturally by the body’s own protein recycling processes, the same way your dog’s immune system handles its own spent antibodies. This is one reason Librela can be an option for dogs who can’t tolerate NSAIDs due to liver or kidney concerns, though each dog’s situation is different.
Some dogs show improvement within the first week, but it can take two or three monthly doses to see the full effect. The antibody needs time to reduce the pool of active NGF circulating in the body and around the joints.
Side Effects and Safety Profile
Global pharmacovigilance data covering over 18 million doses sold worldwide found an overall adverse event rate of about 9.5 events per 10,000 treated animals. That places the overall reporting rate below 0.1%. The most commonly reported issue was a perceived lack of effectiveness, followed at lower frequencies by increased thirst, unsteady movement, increased urination, loss of appetite, lethargy, and vomiting. All of these were classified as rare, meaning they occurred in fewer than 1 in 1,000 treated dogs.
In July 2024, the FDA recommended updated labeling based on post-approval reports. The revised label lists adverse events organized by body system, with neurologic signs (unsteady gait, seizures, weakness in limbs, loss of coordination) reported most frequently, followed by general signs like appetite loss and lethargy, then urinary and gastrointestinal effects. Deaths, including euthanasia, have been reported as outcomes of some of these adverse events, though the FDA notes that not all adverse events are reported and a direct causal link can’t always be confirmed from these data alone.
Dogs That May Not Be Candidates
Librela has not been evaluated in dogs younger than 12 months, so it’s not approved for puppies. It also hasn’t been studied in dogs with a cruciate ligament rupture within the previous six months. Because NGF plays a role in the heart and blood vessels, the long-term effects in dogs with cardiac disease are unknown, and your vet may weigh this carefully.
Repeated dosing can sometimes trigger the immune system to produce antibodies against bedinvetmab itself, which could reduce the drug’s effectiveness over time. This is a known possibility with any monoclonal antibody therapy. If your dog initially responds well but seems to lose benefit after several months, this is one possible explanation worth discussing with your vet.
The safety of Librela in pregnant, breeding, or lactating dogs has not been specifically established in published data, so it’s typically avoided in those populations as a precaution.